H.C. Wainwright has reiterated its Buy rating for BridgeBio Pharma (NASDAQ:BBIO) with a $120.00 price target. This decision follows promising exploratory analyses from the PROPEL 3 study for achondroplasia and strong Q2 2026 revenue, which surpassed analyst estimates due to robust Attruby sales. Other firms like Piper Sandler, Canaccord, and Mizuho have also raised their price targets for BridgeBio Pharma.

Build-A-Bear Workshop, Inc. (NYSE:BBW) has declared a quarterly dividend of $0.23 per share, payable on October 8th to shareholders of record as of September 24th, with an ex-dividend date of September 24th. This represents an annualized dividend of $0.92, yielding 3.3%, and is well-covered by the company's earnings with a current payout ratio of 21.5%. Despite exceeding earnings estimates in its last quarter, the company's revenue fell short of consensus forecasts, and its shares opened near their 52-week low.

Candel Therapeutics has appointed Martine Zimmermann, PharmD, to its Board of Directors, effective September 8, 2026. Dr. Zimmermann brings over 30 years of global regulatory affairs and quality expertise, which will be crucial as Candel prepares for the Biologics License Application (BLA) submission for aglatimagene besadenovec and moves towards potential commercial readiness. Her experience is expected to strengthen the Board's strategic perspective on regulatory approval and commercial launch.

Candel Therapeutics Inc. has appointed Martine Zimmermann, PharmD, to its Board of Directors, bringing over 30 years of global regulatory affairs and quality expertise. This appointment comes as the biopharmaceutical company prepares for a Biologics License Application submission for its investigational drug, aglatimagene besadenovec, in late 2026. Aglatimagene has received FDA Fast Track and Regenerative Medicine Advanced Therapy Designations for localized prostate cancer.

BTIG Research has reiterated a "Buy" rating for Brainsway (NASDAQ:BWAY) with a $20 price target, suggesting a potential upside of 38.8% from its current price. Brainsway exceeded quarterly expectations, reporting $0.14 EPS against an estimated $0.10, and revenue of $17.11 million versus $16.54 million expected. The company has an overall "Moderate Buy" consensus from analysts with an average price target of $18.20.

Aprea Therapeutics, Inc. (Nasdaq: APRE) announced that its President and CEO, Oren Gilad, Ph.D., will present at the H.C. Wainwright 28th Annual Global Investment Conference from September 14-16, 2026. The presentation will be available via webcast on September 14 at 4:30 PM ET, and investors can register for the event and arrange one-on-one meetings with management. Aprea Therapeutics is a clinical-stage oncology company developing targeted therapies for biomarker-defined cancers.

BioCardia, Inc. will present its CardiAMP regulatory and corporate progress at the H.C. Wainwright 28th Annual Global Investment Conference. Peter Altman, Ph.D., President and CEO, will provide updates on the CardiAMP autologous cell therapy's potential regulatory approval in Japan and the US, the ongoing CardiAMP HF II pivotal trial, and the company's Helix transendocardial delivery and Heart3D fusion imaging platforms. BioCardia is preparing for a Shonin pre-market regulatory submission in Japan and advancing a follow-on De Novo pre-submission for its Helix platform.

AGCO Corporation outlined its growth strategy at the Jefferies Global Industrials Conference 2026, focusing on a cyclical recovery led by North America and long-term initiatives. The company is emphasizing the global expansion of its Fendt brand, the growth of its PTx precision technology business, and a shift towards proactive, digital parts and service models. Despite challenges like tariffs and competition, AGCO aims for 14-15% operating margins by 2029, showcasing confidence in its valuation and strategic execution.

This article reports on the filing of a Form 8K by Biocardia Inc. on September 10, 2026. The brief announcement provides no further details regarding the content of the Form 8K filing.

This article announces that Biocardia Inc. (BCDA) has filed a Form 8K for September 10, 2026. The filing is a routine disclosure of significant events that investors should be aware of, with the stock showing a slight decrease at -0.91%.